<DOC>
	<DOCNO>NCT01803373</DOCNO>
	<brief_summary>The purpose study test relative bioavailability ( extent rate drug take body ) TMC207 follow administration two pediatric formulation TMC207 take without food healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability TMC207 Following Single-Dose Administrations Two Pediatric Formulations Healthy Adult Participants</brief_title>
	<detailed_description>This open-label ( study staff participant know identity treatment assign ) , 3-way cross-over ( method use switch participant one treatment another treatment ) study . Three panel 12 healthy adult participant enrol . Within panel , participant randomly ( chance ) assign 1 6 treatment sequence receive 3 formulation TMC207 randomize order . The 3 formulation TMC207 refer Treatments A , B , C. In Treatment A , participant receive single 100-mg dose TMC207 formulate 100-mg tablet ( reference formulation ) . In Treatment B , participant receive single 100-mg dose TMC207 formulate 20-mg water dispersible ( dissolvable ) tablet ( i.e . 5 tablet ) ( pediatric formulation 1 ) . In Treatment C , participant receive single 100-mg dose TMC207 formulate granule 5 gram ( 20 mg/g ) ( pediatric formulation 2 ) . Each treatment separate 4 week . Participants Panel 1 receive treatment standardize breakfast , Panel 2 receive treatment yogurt , Panel 3 receive treatment 10-hour overnight fast ( without food ) . The duration treatment period study 8.5 week ( include 4 week treatment ) .</detailed_description>
	<mesh_term>Bedaquiline</mesh_term>
	<criteria>Healthy participant basis physical examination , medical history , vital sign , electrocardiogram ( ECG ) , result blood biochemistry hematology test urinalysis perform screen Must Body Mass Index ( BMI , weight kg divide square height meter ) 18.5 30.0 kg/m2 , extremes included Women must postmenopausal least 2 year negative serum pregnancy test screen negative urine pregnancy test Day 1 Men must agree use highly effective method birth control ( eg. , male condom either female intrauterine device , diaphragm , cervical cap hormone base contraceptive female partner ) sexual intercourse female partner childbearing potential , donate sperm study 6 month receive last dose study drug . Men vasectomy female partner childbearing potential must agree use male condom study 6 month receive last dose study drug Participants must nonsmoker least 3 month prior screen Human immunodeficiency virus type 1 ( HIV1 ) type 2 ( HIV2 ) infection confirm screen Hepatitis A , B C infection confirm screen A positive urine drug test alcohol breath test screening . Urine test presence amphetamine , barbiturate , benzodiazepine , cocaine , methadone , opioids History currently active disease condition Investigator consider clinically significant , opinion Investigator , participation would best interest participant ( eg , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>TMC207</keyword>
	<keyword>Bedaquiline</keyword>
	<keyword>R207910</keyword>
</DOC>